Pharmacopeia

Canonical comparison

Master Compare

Compare candidate-facing canonical Pharmacopeia fields side by side. Isolated AI-draft proposals are never included.

3selected

Field	CLOPIDOGREL Haematology · Haematology · Level 2	TICAGRELOR Haematology · Haematology · Level 2	PRASUGREL Haematology · Haematology · Level 2
Mechanism of action	Prodrug. Hepatic activation to active agent (Thiol derivative, by oxidation and hydrolysis) which is an ADP receptor antagonist - Irreversible inhibition of P2Y12 receptor at platelet surface → Inhibits activation of GPIIb/IIIa → Inhibits platelet activation	Allosteric, reversible antagonist at P2Y12-R (an ADP receptor), preventing activation of glycoprotein IIb/IIIa→ prevents platelet crosslinking	Irreversibly binds the P2Y12-R (an ADP receptor), preventing activation of glycoprotein IIb/IIIa→ prevents platelet crosslinking
Absorption	- PO. BA 50% - 600mg loading. 75mg maint.	BA=40%	—
Protein binding	95% protein binding,	—	—
Volume of distribution	Vd unknown	—	—
Metabolism	- Hepatic CYP450 2C19 + Esterases to Inactive metab	Metabolized by CYP3A4	Prodrug- 1 step metabolism Less susceptible to CYP polymorphism and CYP inhibition or induction than Clopidogrel
Excretion	- Renal and faecal elimination	—	—
Half-life	- T1/2b 7 hours parent drug (30mins metab) Dur: life of platelet	—	—
Adverse Effects Toxicity	Bleeding TTP Agranulocytosis, Neutropenia Significant drug interactions as requires activation by CYP450	—	—
Class Group	Antiplatelet	Antiplatelet	Antiplatelet
Introduction	ADP Receptor Antagonist - Thienopyridine	ADP Receptor Antagonist - Thienopyridine	ADP Receptor Antagonist - Thienopyridine Prodrug
Legacy Cicm Level	Level 3	Level 3	Level 3
Main Action	Platelet inhibition	Platelet inhibition	Platelet inhibition